BNP Paribas Exane upgraded Clorox (NYSE:CLX) from an “underperform” to a “neutral” rating. Despite this upgrade, the consensus among analysts remains a “Reduce” with an average price target of $117.93, while the stock currently trades around $121.47. Clorox recently reported a slight EPS miss but revenue that modestly beat estimates, though it was down year-over-year.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Clorox (NYSE:CLX) Raised to Neutral at BNP Paribas Exane
BNP Paribas Exane upgraded Clorox (NYSE:CLX) from an “underperform” to a “neutral” rating. Despite this upgrade, the consensus among analysts remains a “Reduce” with an average price target of $117.93, while the stock currently trades around $121.47. Clorox recently reported a slight EPS miss but revenue that modestly beat estimates, though it was down year-over-year.